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Abstract: Marine invertebrates provide a rich source of metabolites with anticancer activities and
several marine-derived agents have been approved for the treatment of cancer. However, the limited
supply of promising anticancer metabolites from their natural sources is a major hurdle to their
preclinical and clinical development. Thus, the lack of a sustainable large-scale supply has been
an important challenge facing chemists and biologists involved in marine-based drug discovery.
In the current review we describe the main strategies aimed to overcome the supply problem. These
include: marine invertebrate aquaculture, invertebrate and symbiont cell culture, culture-independent
strategies, total chemical synthesis, semi-synthesis, and a number of hybrid strategies. We provide
examples illustrating the application of these strategies for the supply of marine invertebrate-derived
anticancer agents. Finally, we encourage the scientific community to develop scalable methods to
obtain selected metabolites, which in the authors’ opinion should be pursued due to their most
promising anticancer activities.
Keywords: eribulin; trabectedin; mycalamide A; spongistatin 1; stelletin A; monanchocidin A;
phenylmethylene hydantoin; frondoside A; discodermolide
1. Introduction
The marine environment is by far the major reservoir of biodiversity on the planet Earth and
represents the biggest source of the untapped chemical richness that has claimed a considerable
attention from the health science communities [1]. Intensive research on the naturally derived
metabolites from terrestrial plants and microorganisms as well as their semi-synthetic analogues
has led to the approval of several agents that have enriched the anticancer therapeutic arsenal, mainly
in the last two decades [2–7]. In addition, Herculean efforts from academic research institutions and
pharmaceutical companies on the bioprospection of the marine ecosystem have revealed a significant
number of lead structures as potential chemotherapeutic candidates, exhibiting promising anticancer
effects in in vitro and in vivo cancer models [8–12]. Furthermore, marine natural products’ usefulness
has been also extended to the identification of new molecular targets providing a wider approach
for the development of new anticancer agents. Consequently, the dynamic pharmaceutical pipeline
comprising several candidates in different stages of clinical development raises hope that several of
these candidates may ultimately provide alternative therapeutic tools for cancer treatment [13,14].
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Among marine organisms, invertebrates have been the mainstream source in marine-derived
drug discovery, contributing approximately to 65% of the marine natural products reported to
date, with sponges serving as the most productive source of new anticancer agents in preclinical
development [15]. The identification and characterization of the ecological role of complex secondary
metabolites produced by marine invertebrates has also led to the discovery of several lead structures
displaying relevant pharmacological properties against a wide range of molecular targets [16–18].
Linked to the adaptation to the marine ecosystem, these secondary metabolites improve marine
invertebrate’s survival by providing chemical defense and adaptation to the marine physical
and chemical extreme conditions, compensating their sedentary lifestyle and lack of physical
protection [19–23]. Simultaneously, the theoretical concept that these chemical weapons act by
interfering with biological receptors and enzymes from co-existing marine competitors and predators,
raised the hypothesis that several of those compounds could also interfere with molecular targets
involved in carcinogenesis. That hypothesis has been notably supported by the relevant and exciting
number of marine invertebrate-derived lead structures with clinical relevance, displaying anticancer
properties and targeting tumors with specific and non-specific cytotoxic effects by suppressing several
molecular targets [24–27].
While the discovery of the nucleosides spongouridine (1, Figure 1) and spongothymidine
(2, Figure 1) from the sponge Cryptotethya crypta in the early 1950s by Bergmann and Feeney [28,29],
can be considered as the first steps in the development of marine-inspired anticancer agents, it
was the cyclic peptide didemnin B (3, Figure 1), originally reported from the encrusting ascidian
Trididemnum solidum [30], that was approved as the first marine naturally occurring candidate to
proceed into clinical trials as an antitumor agent. Despite its promising and early successes against
several human cancer cell lines, the Phase II clinical trial was terminated in the 1990s by the NCI
(National Cancer Institute), due to didemnin B toxicity [31]. However, those preliminary and inspiring
efforts along with the improvements in sampling and scuba techniques as well as spectroscopic and
spectrometric technologies, encouraged and led to the development of several research programs
focused on the bioprospection and characterization of marine-invertebrate derived compounds and
assessment of their potential anticancer properties [32,33]. Mainly in the last two decades, the intensive
efforts and focus on marine invertebrates as prolific producers of anticancer candidates and the
development of synthetic analogues derived from natural prototype structures, keeps exponentially
feeding the preclinical and clinical investigation pipeline [13,14,34]. While the majority of these
potential candidates exhibiting potent and selective anticancer effects remain in preclinical investigation
stages, the current oncological clinical pipeline consists of four marine-inspired anticancer drugs
approved by the FDA and EMA, and 18 candidates in clinical trials [35]. Notably, the majority of these
compounds correspond to analogues of natural lead structures originally reported as being sourced
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As of the end of 2015, the current marine anticancer pharmaceutical pipeline consists of seven
marine-derived approved drugs. Consistent with the major focus on marine invertebrates as
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sources of pharmacologically active lead structures, it is not surprising that the biggest slice of the
anticancer agents so far approved and in clinical development stages are classified as derived from
marine invertebrate-derived metabolites, or suspected to be produced by associated microorganisms,
as detailed in a following section.
The first marine-inspired drug to receive FDA approval was cytarabine (4, Figure 2), receiving
its approval in 1969 for the treatment of acute myelogenous leukemia. The synthetic pyrimidine
nucleoside was developed from the spongean nucleoside spongothymidine (2, Figure 1). Even
nowadays, cytarabine is the mainstream drug for the treatment of acute myelogenous leukemia
under the tradename (Cytosar-U®), being also used in combination therapy for the treatment of
acute lymphoblastic leukemia and chronic myelogenous leukemia [36,37]. More recently, a liposomal
formulation (DepoCyt®) was approved both by the FDA and EMA for the prevention and treatment
of lymphomatous meningitis [38,39]. Furthermore, cytarabine is currently being evaluated against
several types of cancer with distinct etiologies, with 278 and 132 active studies being listed in the US
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Figure 2. Structures of cytarabine (4), trabectedin (5), halichondrin B (6), eribulin (7),
monomethylauristatin E (8) and dolastatin 10 (9).
Despite the early reports on trabectedin’s (5, Figure 2) remarkable anticancer properties, it was
only in 2007 that the antineoplastic marine natural product received market authorization by the EMA
under the tradename Yondelis® for the treatment of advanced soft tissue sarcoma and later, for the
treatment of recurrent platinum-sensitive ovarian cancer in combination therapy [42]. Very recently,
Yondelis® was also approved by the FDA for the treatment of liposarcoma and leiomyosarcoma as
the 2nd line therapy [43]. Yondelis® development was significantly delayed due to its low natural
abundance and several approaches were applied to overcome the scale-up limitation. Due to its
interesting multi-strategy development, a detailed case study on Yondelis® is presented later in
this review.
The naturally occurring macrocyclic lactone polyether halichondrin B (6, Figure 2), initially
reported from the Japanese sponge Halichondria okadai in 1985 [44,45], led to the development of eribulin
mesylate (Halaven®) (7, Figure 2). With enhanced anti-tumor activity, the structurally simplified
synthetic variation of halichondrin B, retained the tubulin inhibitory properties, being approved by
the EMA and FDA to treat locally advanced or metastatic breast cancer, in patients who have received
at least two prior chemotherapy regimens for late-stage disease [46,47]. Additionally, Halaven® is
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also used in the US for the treatment of liposarcoma [47]. At the time of writing, a total of 54 ongoing
clinical trials have been listed in European and US databases [48,49].
Approved in 2011 by the FDA and receiving a conditional approval by the EMA in 2012 for
the treatment of relapsed or refractory CD30+ Hodgkin lymphoma and systemic anaplastic large
cell lymphoma, brentuximab vedotin (Adcetris®) was the most recent marine-inspired anticancer
agent drug to receive market authorization [50,51]. The immunoconjugate Adcetris® consists of the
combination of monomethylauristatin E (8, Figure 2) linked to an antibody targeting the membrane
protein CD30. Monomethylauristatin E corresponds to a semi-synthetic analogue of the linear
depsipeptide dolastatin 10 (9, Figure 2), originally reported by Pettit’s group from the sea hare
Dolabella auricularia [52], which reached Phase II trials but was dropped due to associated toxicity and
lack of efficacy [53,54].
While the clinical development of several candidates has been stopped predominantly due to
lack of efficiency and toxicity, the failure of promising marine-derived anticancer candidates that
frequently do not even reach clinical trials has been partially attributed to limitations of the scale
up process [6]. The typical long time periods generally involved in the drug discovery process from
natural sources, and the difficulties in re-accessing the marine source of the samples due to ecological
considerations or even governmental policies, have delayed or even stopped the development of
several clinical candidates [55]. Drug development based on the collection from natural populations is
also hampered by insufficient and unsustainable quantities of metabolites produced by the animals,
often at concentrations below milligrams per kilogram of invertebrate biomass [56], as well as low
invertebrate populations [34,57]. While the concentrations of these promising clinical candidates
may usually be sufficient for their chemical characterization and preliminary evaluation of the
pharmacological profile, they are far from providing a sustainable supply for pre-clinical and clinical
development, demanding quantities in a gram range, or future commercialization where annual needs
between 1 and 5 kilograms per year are usually estimated [55]. However, several new approaches
have been developed aiming to address this major limitation as discussed in the current review.
2. Solutions to the “Supply Problem”
2.1. Biosynthetic Origin of Marine Invertebrate Metabolites
The recent findings indicating that marine invertebrate-associated microbes may be the true
producers of secondary metabolites with potential clinical applications, namely in oncology, can
provide viable approaches for the sustainable supply of intermediate or even lead structures.
This hypothesis has attracted considerable interest and represents an exciting alternative since, unlike
marine animal resources, the supply issue is less problematic for marine microorganisms through
animal-independent or even culture-independent production methods [58].
Marine invertebrates as well as plants and fungi have co-evolved with bacterial symbionts, with an
expanding list of pharmacologically active natural products being identified in symbiotic bacteria [59].
It is long known that marine invertebrates, mainly sponges, harbor a vast and diverse set of associated
microorganisms, many of which are true symbionts. A 16S ribosomal DNA library construction
and in situ hybridization analysis have allowed the phylogeny of such microbial communities to be
uncovered [60,61]. Particularly in sponges, the associated microbiota, mainly extracellularly located,
can contribute up to 40%–60% of the animal biomass [62,63]. The co-evolution of marine invertebrates
together with endo- and epibiotic microorganisms, that constantly metabolize invertebrate products
and synthesize numerous secondary metabolites, points to a chemo-ecological strategy allowing
chemical defense, adaptation of the host to the marine environment, and nutrition [64–66].
While it is clear that several metabolites are clearly located in an invertebrate tissue and a microbial
origin seems improbable, in some cases compounds isolated from sponges appear to be synthesized
by their associated microorganisms [67,68]. Despite being less studied than sponges, the microbial
diversity associated with bryozoans and ascidians has been also characterized with several secondary
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metabolites suspected to be produced by symbiotic microbes [69–71]. The early suspicions that
symbiotic bacteria are the true metabolic sources of several compounds were based on structural
homology between some invertebrate-derived compounds from taxonomically distant taxa of marine
macroorganisms as well as their resemblance to bacterial natural products [72–75].
Marine-derived fungi have provided a significant number of candidates with promising
anti-cancer properties [76]. However, based on the chemical pattern of secondary metabolites
produced by invertebrate-derived fungi, it is doubtful that fungi are metabolic producers of compounds
reported from marine invertebrates [76,77]. Instead, several structurally complex polyketides and
nonribosomal peptides reported from marine invertebrates, are most likely produced by bacteria, since
the biosynthetic machinery responsible for their production, consisting on polyketide synthase (PKS)
and nonribosomal peptide synthase (NRPS) pathways, has only been described in bacteria and lower
eukaryotes, being extremely rare in animals [74,78].
Several naturally occurring chemotherapeutic candidates reported from marine invertebrates that
progressed to pre-clinical or clinical development, are hypothesized to have a microbial biosynthetic
source [79]. A representative example is didemnin B (3, Figure 1) recently reported as a metabolic
product of the α-proteobacterium Tistrella mobilis collected from marine sediments that while not being
conclusive about the metabolic source, indirectly suggests a microbial origin [80]. Also for the lead
antitumor agent halichondrin B (6, Figure 2), circumstantial evidence points to a microbial source due
to its isolation from several classes of Porifera from distinct geographical sites, as well as the structural
homology with some bacterial polyethers [81,82]. Stronger evidence exists for the antimitotic agent
dolastatin 10 (9, Figure 2) isolated from its cyanobacterial diet of the genera Simploca and Lyngbya,
along with several dolastatin-like analogues [83,84].
Another example is the PKC inhibitor bryostatin 1 (10, Figure 3) currently being evaluated
in a Phase II trial in Alzheimer patients and listed in several Phase I and II clinical trials against
hematological and solid tumor cancers [85,86]. There is almost conclusive evidence that bryostatin 1 is
in fact produced by a bacterial symbiont due to the discovery of its putative PKS-I genes, in the genome
of the bryozoan symbiont γ-proteobacterium Candidatus Endobugula sertula through a metagenomic
strategy [87,88]. Further evidence is derived from the observation that Bugula neritina colonies treated
with antibiotic experienced pronounced decrease on the expression of the PKS gene cluster as well as
in bryostatin 1 production [87,89].
The depsipeptide kahalalide F (11, Figure 3) reached Phase II trials in Europe in 2004 as an
anticancer agent in patients with non-small cell lung cancer stage IIIB (2004-001253-29). Firstly isolated
by Hamann and Scheuer [90] from the herbivorous mollusk Elysia rufescens, kahalalide F was reported
three years later in its algal diet Bryopsis sp. [91], suggesting an alternative source. Later, kahalalide
F and additional analogues were described from Bryopsis and E. rufescens associated bacteria [92],
providing robust evidence that the metabolic source corresponds to a bacterial symbiont.
So far providing only a limited circumstantial evidence, the isolation of the antimitotic diterpene
eleutherobin (12, Figure 3) from distinct taxa such as the soft coral Eleutherobia sp. [93] and the
encrusting coral Erythropodium caribaeorum [94], also points to a common symbiotic microorganism as
the true producer. Several additional examples of marine animal compounds presumably originated
in symbiotic bacteria have been summarized in relevant reviews [71,95–98].
Despite the vast number of secondary metabolites sharing close structural similarities between
an invertebrate-derived and a bacterial compound, this argument constitutes compelling but indirect
evidence. The intimate metabolic associations between invertebrate hosts and associated microbes are
extremely difficult to unequivocally ascribe the production of the compounds to the host invertebrate,
the symbionts or even to a joint biosynthesis [75,99]. In fact, conclusive evidence exists only in a very
limited number of cases [98].
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Figure 3. Structures of bryostatin 1 (10), kahalalide F (11), eleutherobin (12), avarol (13), and
manzamine A (14).
Accurate and high resolution mass spectrometry techniques such as MALDI-TOF-imaging
are powerful tools allowing the detection of low quantities of compounds and consequently the
identification of secondary metabolites in microorganisms and hosts, as well as the taxonomic
identification of individual microorganisms based on their mass fingerprints in complex mixed species
assemblages [100]. However, the identification of metabolic sources based on compound localization
methods such as microanalysis by mass spectrometry, or through classical approaches such as HPLC
and NMR a alysis, cannot be considered completely reliable since it is plausible to expect that t e
location of a cert in s condary metabolite in particular cell type can derive from transfer mechanisms
between individual cells by export or sequestration mechanisms, and the biosynthesis of metabolic
precursors or intermediates can have an invertebrate or microbial origin [101,102]. For the development
and selection of sustainable supply tools allowing the large-scale production of those potential clinical
candidates, an unequivocal identification of the biosynthetic producer and the distinction between the
collected and metabolic source is highly advisable. An unambiguous assignment of the biosynthetic
origin from a complex assemblage of marine org nisms thus has to originate at th chemical protein or
genetic level, and the increasing number of bacterial PKS genes discovered through metagenomics
have strengthened the evidence that a notable number of antitumor compounds discovered from
invertebrates are in fact bacterial metabolic products [95,97,103].
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2.2. Marine Invertebrate Aquaculture
While the wild harvest of marine invertebrates is considered plausible for pre-clinical studies,
the collection of larger populations for clinical development and commercial production of an
eventual clinical candidate is environmentally unsustainable due to insufficient or inaccessible natural
populations and the typical low yields of bioactives [56,104]. Even so, halichondrin B (6, Figure 2)
pre-clinical development was started by harvesting more than one metric ton of the rare sponge
Lyssodendoryx sp. from natural populations to afford only 310 mg of pure compound [105]. Also,
bryostatin 1 (10, Figure 3) progressed to Phase I clinical trials through the wild harvest of nearly 13 ton
of the bryozoan Bugula neritina yielding 18 g of the anticancer candidate [106].
As an alternative to wild harvesting, aquaculture may represent a plausible strategy in a few
cases mainly through in situ (mariculture) or sea-based farming, with some successful cases leading
to improved growth rates compared to the ones reported from natural populations [107,108]. As an
example, the sea-based aquaculture trial of the sponge Mycale hentscheli, reported to produce the
microtubule-stabilizing agent peloruside A, displayed an impressive growth rate of 3000% in eight
months [109], with an estimated supply of one gram of peloruside A per 100 kilograms of sponge
biomass [110]. With a disappointingly lower yield, the mariculture of another microtubule-stabilizing
agent, eleutherobin (12, Figure 3), led only to the isolation of 12 g per ton of the gorgonian
Erythropodium caribaeorum [111]. The sea farming is clearly dependent on the in situ conditions posing
serious limitations, such as the difficulty in controlling culture parameters and susceptibility not only
to environmental changes but also pathogens [112–114]. Additionally, environmental changes can also
lead to a distinct associated microbial consortium, which may be critical for metabolites produced by
bacterial symbionts [109].
Intensive efforts have also been made in the optimization of ex situ or land-based invertebrate’s
culture, mainly driven by the possibility of better controlling the farming conditions and optimization
of metabolite production [115]. However, despite the potential to obtain a continuous annual growth
and avoid disease outbreaks, with a few exceptions [116–119], ex situ farming has so far failed to
produce a consistent biomass yield, since it is difficult to mimic the complexity of the invertebrate´s
natural habitat. While food quantity and quality requirements are indicated as the primary factors
for significant growth rates [120], species-specific conditions, such as water pH, salinity, temperature
levels, light exposure, and dissolved oxygen, all need to be controlled for feasible commercial
farming [113,114]. Furthermore, it is obviously impossible to assure an efficient feeding supply
and waste removal in a closed system as compared to the unlimited volumes of seawater in the natural
habitats [112].
The production of secondary metabolites by marine invertebrates is generally quite variable,
depending on several physical, chemical, and biological induction factors [114]. Thus, even with an
optimal invertebrate growth rate, due to the lack of knowledge of the induction factors it is not certain
that a specific bioactive compound will be produced in an unnatural and controlled environment.
In fact, as referred by Koopmans et al. [121] several examples support a possible activation of metabolic
pathways in sponges, which are derived from chemical and physical aggression factors present in an
unnatural environment.
While in certain cases, such as the production of up to three g of the antipsoriatic and potent
cytostatic agent avarol (13, Figure 3) per kilogram of sponge Dysidea avara wet weight [122], invertebrate
farming appears to be a plausible supply strategy, most species are slow-growing and, in the majority
of the cases, the production of the desired metabolite is low as demonstrated with halichondrin B and
bryostatin 1. Based on many marine sponge aquaculture trials, it is now generally agreed that sea
farming appears to be more successful than ex situ. Despite its limitations, such as the vulnerability to
destruction by climatic and environmental events, risk of infection and costs associated with metabolite
extraction, sea-based aquaculture gives faster invertebrate growth rates and higher yields of metabolite
production [114,121,123].
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2.3. Invertebrate and Symbiont Cell Culture
While whole-animal culture has been used for years as the main supply strategy, in cases where
the desired compound is produced by the marine invertebrate, it is also plausible to consider cell
culture. The controlled and continuous growth of a specific type of invertebrate cell in bioreactors is a
tempting alternative. However, with the main focus on sponge cell culture, only modest progress has
been achieved to date [124,125].
Since the majority of sponge cells are totipotent, it has been attempted to obtain homogeneous
sponge cell populations that have the ability to produce a specific metabolite in vitro. However, a
continuous cell growth of primary cells has not been achieved [113]. Recently, primmorphs, a specific
type of cells produced from primary cells in suspension, attracted considerable interest. Notably, it
was observed that primmorphs formed in the presence of symbionts, leading to the production of a
certain metabolite, even if the latter has a microbial origin [126].
Analogously to the ex situ aquaculture of marine sponges, it is a Herculean task to not only
simulate their natural habitat, but also the cells’ own micro-environment, which may cripple cell
growth, and ultimately secondary metabolite production [127]. Additionally, it is clear that the
promotion of sponge cell culture growth is also dependent on several specific growth factors and
inorganic demands that should be supplemented through specific substrates, in addition to the very
specific and strict control of physical parameters [125,128]. Furthermore, for the specific production of
potential anticancer secondary metabolites usually displaying cytotoxic effects, cell culture via cell
suspension or primmorphs, appears not to be a recommended approach due to the interference on the
growth of sponge cells. Notably, Müller’s promising studies led to the successful in vitro production of
avarol (13, Figure 3) from the primmorphs of the sponge Dysidea avara [129]. Part of the success may
be explained by the avarol’s cytostatic rather than cytotoxic properties, which do not induce cell death
of the sponge primmorphs [129].
In their economic analysis of the supply of marine sponge-derived metabolites via sponge
aquaculture or sponge primmorphs, Sipkema et al. [123] clearly indicate that to establish a viable
large-scale supply of secondary metabolites through sponge cell culture, the formation of primmorphs
would require a significantly higher biomass of animal compared to the required biomass for the direct
extraction of a target compound from the sponge. Since the number of variables that interfere with
invertebrate cell growth and the required factors that allow for their in vitro culture are still vastly
unknown, it is clear that, despite the exciting progress achieved to date, the adaptation of this strategy
to the large-scale production of invertebrate metabolites still remains a mirage.
As previously mentioned, the detection and/or isolation of secondary metabolites from
microorganisms, namely bacterial endosymbionts made marine microorganism culture-dependent
approaches a promising supply strategy. Fermentation still plays a key role in the drug development of
pharmaceuticals, and the possibility of obtaining a sustainable and economically feasible supply based
on microbial large-scale cultures, frequently improves the chances for a potential clinical candidate to
progress to clinical trials [75]. Another advantage of in vitro microbial culture methods is the possibility
of manipulating different growth parameters to increase the yield of secondary metabolites [130].
The identification of several strains of marine-derived microorganisms isolated from marine
invertebrates as well as their use to furnish pharmacologically active compounds has been successfully
demonstrated through cultivation-dependent approaches [131–135]. However, these strains are almost
exclusively surface-associated microorganisms and usually marine facultative [130]. In fact, while
most microbial-derived pharmaceuticals are known from culturable strains, genomic studies have
revealed that an estimated 99% of both terrestrial and marine bacteria remain uncultured through
standard laboratory methods [136,137]. The slow progress on the development of culture-dependent
approaches for the production of marine microorganisms, particularly obligate marine bacteria and/or
endosymbionts, and the lack of appropriate literature on the isolation procedures and standardized
culture conditions, will certainly continue to contribute to this undesirable scenario [34,98].
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It is possible that in near future, the majority of the bacterial symbionts associated with marine
invertebrates will still remain unculturable ex hospite due to host-specific nutrients, cell-cell interactions,
and additional not yet defined metabolic factors that are required for growth [138]. While it is
unachievable to simulate all the specificities of the marine environment, including the interaction with
an invertebrate host or other microbes, several successful attempts have been made to improve the
culturability of marine microorganisms based on the simulation of their natural environment [139].
The control of physical cultivation conditions such as temperature or aeration, or media composition
and incubation time have been taken into account to assure or even maximize the production of a
certain compound, and several successful approaches have been already fruitful [139–143]. However,
even if hypothetically the optimization of physical cultivation conditions can be achieved allowing a
controlled and significant growth of a marine symbiont, the target compound might not be produced
due to the absence of the required environmental signals [78].
Despite the abovementioned limiting factors, the in vitro production of a compound by a
bacterial symbiont has been achieved by Hill’s group. Successful examples are represented by the
production of kahalalide F (11, Figure 3) obtained from the cultures of bacteria Vibrio mediterranei [92],
and the isolation of the antimetastatic alkaloid manzamine A (14, Figure 3) from the culture of
Gram-positive bacterium Micromonospora M42 obtained from the deep-water Indonesian sponge
Acanthostrongylophora sp. [144].
2.4. Culture-Independent Strategies
The privileged access to the marine bacterial biosynthetic machinery through genome mining
has led to the identification of a few putative biosynthetic PKS and NRPS genes responsible for
the production of anticancer lead structures originally described from marine invertebrates [77,145].
In addition to the chemo-ecological relevance, the recent rapid advances in microbial genomics allow
the access and expression of single genes or entire genetic pathways in suitable heterologous hosts
paving the way for the sustainable supply of lead structures produced by unculturable or slow-growing
bacterial symbionts [78,146–148].
The extraction of DNA suitable for heterologous expression from invertebrate bacterial
endosymbionts is extremely challenging due to the tight junctions formed. However, this limitation
can often be overcome with metagenomics involving the analysis of eDNA from complex populations
of organisms as well as mainstream bioinformatics tools [145,149–151]. The identification of entire
biosynthetic genes in bacterial symbionts is simplified by the organization of bacterial genes in compact
clusters facilitating their mining and cloning [78]. To fully explore the potential of heterologous
expression, it is indispensable to develop suitable culturable hosts able to efficiently express the natural
products from a taxonomically distant organism [152]. Despite the challenges, several strains of
Escherichia coli, Pseudomonas putida, Streptomyces, among others have been engineered as amenable
hosts to successfully express PKSs and NRPSs from a distinct origin [153–158].
Several gene clusters have been identified from bacterial symbionts, predominantly
trans-acyltransferase PKSs (trans-AT-PKS). Pederin putative trans-AT-PKS cluster was the first
identified cluster from an uncultured Pseudomonas sp. symbiont of a terrestrial beetle [159]. Motivated
by the striking structural similarities between pederin and the spongean antitumor agents onnamide
A (15, Figure 4), theopederin A (16, Figure 4) and irciniastatin A (17, Figure 4), Piel and colleagues
constructed a metagenomic cosmid library from the DNA of the sponge Theonella swinhoei, and through
a clone pooling strategy a gene cluster closely resembling pederin trans-AT-PKS cluster was identified,
thus providing robust evidence on the bacterial origin of the sponge derived metabolites [160].
Additional examples refer to the identification of bryostatin PKS gene cluster in the genome of a
bryozoan bacterial symbiont as previously mentioned [87,88], and the identification of didemnin B
gene cluster in the α-proteobacteria Tistrella mobilis obtained from marine sediments. This suggests
that an alternative supply may be achieved for the anticancer clinical candidate aplidine (18, Figure 4)
through the bacterial production system [80,161].
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However, the landmark achievement in the production of marine bacterial symbiont-derived
metabolites was the successful “shotgun” cloning of the gene cluster encoding a microcin-like
ribosomal pathway responsible for the synthesis of the anticancer peptides patellamide A (19, Figure 4)
and C (20, Figure 4). The sequencing of the entire genome from Lissoclinum patella cyanobacterial
symbiont Prochloron didemni, allowed the patellamide gene cluster in Escherichia coli to be expressed
through the heterologous expression, providing conclusive evidence on the patellamides’ true
metabolic source [162,163].
Notably, in addition to serving as an alternative supply tool for unculturable marine microbes,
metagenomics uncovers also the existence of silent gene clusters, constituting a relevant proportion
of the microbial genome usually inactive through culture-dependent methods. Allowing their
expression may give access to the full metabolic potential of unculturable bacteria making it possible
to discover, isolate, and produce new secondary metabolites, potentially with relevant anticancer
properties [58,100,164,165]. Still, despite the exciting results obtained through metagenomics, the scale
up production of a compound through the heterologous expression methods remains a challenge and
their definitive affirmation as feasible and efficient solutions to deliver sufficient quantities for clinical
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2.5. Total he ical Synthesis
Prior to the 20th century, phar acologically useful olecules ere pri arily obtained fro
their natural sources. ith the tre endous advances in the develop ent of synthetic ethodology
and our ability to synthesize more and more challenging molecules, this paradigm has changed
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and synthesis has become an integral part of not only providing access to the bioactive natural
products, but also their derivatives with improved pharmacological properties. Today, the main
consideration in developing a synthesis of a clinical candidate is not the ability to reach the desired
target, but rather the scalability of the synthetic sequence and the amount of effort, manpower, and
resources this undertaking involves. A case in point, is the clinical development of discodermolide
(21, Figure 4), a polyketide natural product that was isolated from Caribbean deep-sea sponge
Discodermia dissoluta [166]. Discodermolide displayed significant antitumor activity in preclinical
evaluation, but the progression of this natural product toward the clinical development was hampered
by the supply problem. Its occurrence constitutes only 0.002 wt % of the dried D. dissoluta, and this rare
natural source could not provide sufficient quantities of material required for clinical trials. Inspired
by the total synthesis of discodermolide by the Paterson and Smith groups [167,168], Novartis Pharma
AG developed a 39-step synthesis (26 steps in the longest linear sequence) leading to 60 grams of
discodermolide in 2004 [169–172]. The synthesis took 20 months to complete, involved 43 chemists,
and produced the final product in an overall yield of 0.65%, indicating the huge investment of time,
manpower, and resources. However, the provision of 60 grams of discodermolide from the natural
source would have required 3000 kg of the sponge, an amount which probably does not exist. This
accomplishment demonstrates that given enough time, resources, and manpower, total synthesis is
capable of delivering sufficient material for clinical studies.
Of the clinically approved marine invertebrate-derived anticancer drugs, eribulin mesylate
(Halaven®) is manufactured by total synthesis, developed by Eisai Inc. As mentioned in the
Introduction, eribulin is a fully synthetic analogue of halichondrin B and it has been approved
for the treatment of metastatic breast cancer. The structure of eribulin (7, Figure 2) is significantly
simplified compared with halichondrin B (6, Figure 2), but it still contains 19 of the 32 stereocenters
present in the natural product. The foundation for the developed synthesis of eribulin was the total
synthesis of halichondrin B reported by Kishi and coworkers at Harvard University [173]. Shown
here is the endgame of the developed synthetic pathway involving the joining of building blocks 22
and 24, prepared in 13 (2.2% yield) and 18 steps (0.7% yield), correspondingly, from commercial
materials (Figure 5).
DIBAL reduction of the ester functionality in 22 led to aldehyde 23, which was subjected to
an aldehyde-sulfone coupling using BuLi in THF-heptane to produce 25 incorporating the entire
carbon skeleton of eribulin. Oxidation of 25 with Dess-Martin periodinane followed by the selective
removal of the sulfone moiety with samarium(II) iodide gave ketone 27. The macrocyclic ring closure
was accomplished by the Ni(II)/Cr(II)-mediated coupling (Nozaki-Hiyama-Kishi reaction; NHK)
to produce 29. The employment of the asymmetric ligand 28 in this coupling reaction had no
stereochemical consequences as the resulting secondary alcohol was oxidized in the next step to
a ketone, however it produced the highest reaction rates of the many ligands tested. Ketone 30 was
then treated with TBAF to remove the protecting silyl groups and the required ketalization was
achieved with PPTS in CH2Cl2 followed by crystallization from acetonitrile and water to give 32.
The introduction of tosylate at the primary hydroxyl was followed by the treatment with alcoholic
ammonium hydroxide. This resulted in the intermediate formation of an epoxide, which underwent
ring opening with ammonia to give eribulin free base 7. The free base was dissolved in acetonitrile
and treated with ammonium mesylate, the solvent was replaced with CH2Cl2 and the obtained salt
was precipitated with pentane. After drying in vacuo, the resulting eribulin mesylate (Halaven®) was
obtained as an amorphous powder that was suitable for intravenous formulation and administration.
The developed synthesis of eribulin mesylate is reproducible on a multi kilogram scale and is
currently used for the commercial manufacture of this anticancer agent for human clinic. However, the
length of the synthesis, amounting to 30 steps for the longest linear sequence, and low overall yield of
0.16% testifies to the investment of resources for the industrial manufacture of this cancer drug.
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Figure 5. Total synthesis of Halaven starting fro building blocks 22 and 24.
2.6. Semisynthesis
Due to the resources involved in the development of industrial scale manufacture of
pharmaceuticals by total synthesis, semisynthesis involving an elaboration of a structurally related
natural products to produce the desired one can be an important consideration. Of the clinically
approved marine invertebrate-derived anticancer drugs, trabectedin is produced through such
an approach.
Trabectedin (5, Figure 2, Ecteinascidin 743, Et-743) was first is lated in 1990 by Reinhart and
coworkers from the C ribbean tunicate Ecteinascidia turbinat as the most abundant representative of
a group of six cteinascidins: Et-729, Et-743, Et-745, Et-759A, and Et-759B [174–177]. Trabectedin
was tested in h National Cancer I titute (NCI) 60-cell line panel and found to hav potent
antiproliferative activity and mechanism of action distinct from the standard agents in the NCI atabase
as revealed by the COMPARE analysis. Although extensive evaluation of trabectedin in murine
models of human cancer revealed broad activity against xenografts derived from a diverse spectrum
of tumors [178,179], human phase I clinical trials demonstrated prolonged disease stabilization
in soft tissue sarcoma patients [180–182]. Subsequently, after trabectedin’s efficacy in soft tissue
sarcoma patients was confirmed in phase II clinical trials, it was approved in 2007 in the European
Union (Yondelis®) for the treatment of advanced or metastatic soft tissue sarcoma after failure of
anthracyclines and isofosfamide [183]. Further, after a randomized phase III trial of trabectedin in
combination with pegylated liposomal doxoribucin (PLD) demonstrating a significant improvement in
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progression-free survival and overall response over PLD alone [184,185], trabectedin/PLD combination
received approval for the treatment of relapsed platinum-sensitive ovarian cancer in the European
Union in 2009 [186]. Most recently, in October 2015, following the results of a randomized phase III
clinical trials demonstrating better outcomes in either liposarcoma or leiomyosarcoma patients treated
with trabectedin compared to those receiving dacarbazine [187], the US FDA announced the approval
of trabectedin for the treatment of liposarcoma or leiomyosarcoma that is either unresectable or has
metastasized [188]. Since Yondelis’ approval in the European Union in 2007, close to 50,000 patients in
80 countries have benefited from this therapy and its approval in the US will further help address this
unmet clinical need [188].
Extensive preclinical and clinical evaluation of trabectedin followed by its marketing as a cancer
drug has led to the supply problem. Generally, marine natural products not only are present in small
amounts in the producing organism and also possess highly complex structures. Trabectedin, isolated
in 0.0001% yield and possessing bridged multicyclic stereochemically complex structure serves as
an excellent example of problems involved in the provision of sufficient amounts of material for its
development and use as a cancer drug. Initially, bulk collections of the Caribbean tunicate populations
and their extraction followed by purification of trabectedin allowed for provision of the necessary
quantities of material to complete in vitro studies and initiate preclinical evaluation [189].
However, due to the environmental and sustainability considerations of harvesting large amounts
of natural populations [190], PharmaMar, the company that performed the pharmacological evaluation
and was responsible for the ultimate commercialization of trabectedin, initiated a challenging program
of Ecteinascidia turbinata aquaculture and, subsequently, Mediterranean aqua pharms located in the
Balearic Islands, Tunisia, and the Atlantic coast of Spain were established. After several years
of effort PharmaMar produced over 250 metric tons of the tunicate biomass with the trabectedin
content amounting to 5 milligrams per gram on the wet weight basis. However, the isolation of
trabectedin involved complex extraction with several different organic solvents followed by multi-step
chromatography. This led to final yields of 1 milligram per gram. This low yield of the isolated material
combined with the heavy economic impact of the extraction and purification processes highlighted the
inability of the aquaculture method to solve the trabectedin supply problem [189]. Indeed, while these
efforts provided sufficient quantities of the material to continue clinical development, the prospect
of future commercialization of trabectedin necessitated the departure from the dependence on the
natural source and called for the development of a scalable synthetic process.
The first total synthesis of trabectedin was accomplished by Corey’s group [191,192]. It was
based on the proposed biosynthetic route [193,194] that involved a convergent approach consisting of
combining four subunits A, B, C, and D depicted in Figure 6 [189,195,196].
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Retrosynthetic scheme illustrating the convergent approach in Corey’s synthesis
of trab ctedin.
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Synthesis of bridged lactone C commenced with a double ortho-derivatization of MOM
ether-protected sesamol 34 giving tetra-substituted benzaldehyde 35 (Figure 7). Removal of the
MOM group with the subsequent reprotection of the phenolic oxygen as benzyl ether was followed by
the Knoevenagel condensation with a double malonate ester to give α,β-unsaturated derivative 36.
Allyl ester in 36 was removed under hydrogenolytic conditions and the resulting acid was subjected
to the Curtius rearrangement with the subsequent enantioselective alkene hydrogenation to give
Cbz-protected aminoester 37 in 96% ee. Dimethyl acetal was removed with BF3 etherate and the
presence of water and the resulting aldehyde was subjected to the treatment with BF3 etherate and
MS 4A effecting an intramolecular Pictet-Spengler cyclization, which after the removal of Bn and
Cbz groups afforded the desired lactone C. The synthetic sequence leading to the building block C
consisted of 12 steps giving the desired product in 26% overall yield.
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Figure 7. Synthesis of the building block C.
Synthesis of the building block D started with gallic ester 38, which was converted to
benzaldehyde 39 with routine transformations (Figure 8). Knoevenagel condensation with
monomethylmalonate, incorporation of nitrogen with Curtius rearrangement and asymmetric
hydrogenation of the alkene gave Cbz-protected tyrosine derivative 40. Changing the protecting
group on the nitrogen from Cbz to Alloc, methyl ester hydrolysis and the reinstallment of the TBS
ethers gave the desired building block D in 10 steps and 70% overall yield from gallate 38.
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Figure 8. Synth sis of the building block D.
The two buildi g blocks d D wer combined by the mide formati n reacti n prom ted with
2-chloro-1,3-dimethylimidazolidinium hexafluorophosphate (CIP) and 1-hydroxy-7-azabenzotriazol
(HOAt), affording after allylation of the phenoli oxyg n amide 41 (Figure 9). Reduction of the lacton
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functionality in 41 to the corresponding lactol, removal of the TBS ethers and treatment with triflic acid
affected the desired bisannulation to give 43 through the intermediacy of acyliminium ion 42. Partial
reduction of the amide in 43 to the aminal derivative was followed by treatment with KCN in AcOH
to afford aminonitrile 44. This was followed by regioselective triflation of one of the two phenolic
hydroxyls, silylation of the primary alcohol, and introduction of the MOM group on the remaining
phenolic oxygen to give 45. The allyl ether in 45 was hydrogenolytically removed and the two
necessary methyl groups were introduced through reductive amination and Stille coupling resulting in
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Figure 9. Linking building blocks C and D and further manipulations to repare for the incorporation
of fragme ts A and B.
To incorporate the sulfur containi i ge (building block B) the phenol functionality in
int rmediate 46 was oxidized with ben - leninic anhydride to the α-hydroxyketone moiety and
the TBDPS ether was re oved ith TBAF to afford 47 (Figure 10). Intermediate 47 was esterified with
protected cysteine derivative B. Treatment of the resulting ester with Tf2O and DMSO and then with
the Hunig base gave an electrophilic o-quinone methide functionality, which underwent intramolecular
coupling with the thiol group released after the removal of the fluorenylmethyl protection with the
Barton’s base (see 48). Acetylation of the phenolic hydroxyl then gave bridged intermediate 49
incorporating fragments B, C and D. Removal of the Alloc protection and Rappaport deamination
produced ketone 50, which was reacted with the tyramine derivative A under Pictet-Spengler condition
to complete the construction of the multicyclic framework of trabectedin. Finally, removal of the
MOM protecti and conversion of the aminonitrile fu ctionality to the carbinolamine with AgNO3
completed the synthesis. The sequence of reactions leading to trabectedi f om intermediate 46
i volved 11 steps and proceeded in 14% overall yield.
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Figure 10. Incorporation of fragments A and B and completion of the synthesis of trabectedin.
Overall, the synthesis involved 46 steps with 36 of them being part of the longest linear sequence.
The overall yield for the longest linear sequence starting from sesamol 34 was 1%. This is quite
respectable giving the complexity of the structure and the synthesis of trabectedin by Corey’s group
undoubtedly represents an outstanding achievement. Yet, it provided only a temporary solution to
the supply problem and more cost-effective synthetic processes were sought. In 2000, PharmaMar
disclosed a semisynthetic route to trabectedin [197], which was eventually adopted and is used
currently for the industrial preparation of multigram quantities of this cancer drug. The semisynthesis
starts with cyanosafracin B [198] (Figure 11), an antibiotic of bacterial origin, obtained in kilogram
quantities by fermentation of the bacteria Pseudomonas fluorescens [199].
The synthesis commenced by protecting the amino group and the phenolic oxygen with Boc and
MOM functionalities, respectively, followed by the substitution of the methoxy moiety by the hydroxy
group in the quinone ring to give 51 (Figure 11). The quinone ring was then reduced to hydroquinone
and the resulting phenolic oxygens were converted to the methylenedioxy functionality and allyl
ether to produce 52. After the removal of MOM and Boc protecting groups, the liberated amine was
subjected to Edman degradation to give amine 53. Temporary protection of the primary amine as Troc
carbamate, the introduction of the phenolic MOM, removal of Troc with Zn/AcOH was followed by
the substitution of the amino group with the hydroxyl moiety using NaNO2/AcOH to result in 54. The
rest of the synthesis heavily relied on the transformations described in the above-discussed Corey’s
sequences. Thus, the esterification of 54 with the protected cysteine and oxidation of the phenol to
the α-hydroxy ketone in 55 was followed by the sequence of steps leading to the o-quinone methide
formation and intramolecular addition of the thiol to give 56. Finally, MOM removal and Rappaport
deamination led to 57, which was subjected to the Pictet-Spengler reaction and substitution of the
cyano group by the hydroxyl to give trabectedin.
The total synthesis of trabectedin by Corey’s group and the subsequent semisynthetic approach
by the PharmaMar scientists, currently utilized for the industrial preparation, serve as an excellent
demonstration of the ability of synthesis to provide necessary quantities of a pharmacological agent
for its clinical use. Indeed, multistep synthesis of complex natural products, such as those produced
by marine invertebrates, should no longer be regarded as an academic exercise aimed to produce
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milligram quantities of the final product, but rather deserves to be viewed as a serious alternative
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Fig re 11. Se isynthesis of trabecte in fro cyanosafracin .
2.7. Synthetic Access to Marine Invertebrate Metabolites with Promising Anticancer Activities
Table 1 shows the examples of marine invertebrate metabolites selected on the basis of reported
anticancer activities. The table includes metabolites, which we consider to be true promising anticancer
agents as opposed to any marine invertebrate-derived natural products with reported cytotoxicity only.
For such a selection we used any of the following criteria: (1) known modes of action; (2) demonstrated
in vivo activity; or (3) having potential to be selective toward specific types of cancer. From the
discussion in Sections 2.5 and 2.6 it is clear that the number of steps in a synthesis is crucially important
for the feasibility and practicality of material provision, as it determines the manpower, time and
resource input, as well as the amount of waste and byproducts to be handled. Indeed, step count, or
“step economy” as it is often referred to in the synthetic community [200,201], is key to the preparation
of practical quantities of material. Because marine invertebrates are generally a poor source for
metabolite provision, it is our hope that Table 1 will serve as guidance for researchers in the field as to
what promising anticancer agents can be accessed via synthetic approaches.
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Table 1. Selected total or semisyntheses of marine invertebrate metabolites with reported promising anticancer activities.
Natural Product
Total or Semisynthesis
T/S a # of Steps Starting Material Reference
Aaptamine T 5 6,7-dimethoxy-1-methylisoquinoline [202]
4-Acetoxythorectidaeolide A N/A N/A N/A N/A
Adociaquinones A and B T 3 2,5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene [203]
Agelastatin A T 9 D-Aspartic acid [204]
Agosterol A T/S 23 Ergosterol [205]
Aplidine (plitidepsin or dehydrodidemnin B) T 3 D-Proline [206]
Aplyronine A T 15 (R)-3-(benzyloxy)-2 methylpropanal [207]
Aplysiallene T 16 (S,S)-Diepoxybutane [208]
Arenastatin A (Cryptophycin-24) T 14 (D)-N-Boc-tyrosine methyl ether [209]
Austrasulfone N/A N/A N/A N/A
Avarol T 11 Wieland-Miescher ketone [210]
Avarone T 10 Wieland-Miescher ketone [210]
Bastadin 6 T 7 N-Boc-3,5-dibromotyramine [211]
Bastadin 9 N/A N/A N/A N/A
Bastadin 16 T 16 p-benzyloxybenzaldehyde [212]
Batzellines A-D T 12 4-aminoveratrol [213]
Botryllamide A N/A N/A N/A N/A
Bryostatin-1 T 31 1,3-propanediol [214]
Bryostatin-1 T 46 (R)-Isobutyl lactate [215]
Candidaspongiolides A and B N/A N/A N/A N/A
Caulibugulone A T 5 2,5-dihydroxybenzaldehyde [216]
Cephalostatin 1 T 33 trans-androsterone [217]
Chondropsin A N/A N/A N/A N/A
Clionamine B S 11 Tigogenin [218]
Comaparvin N/A N/A NA N/A
Cortistatin A T 19 Prednisone [219]
Crambescidin-816 N/A N/A N/A N/A
Cytarabine N/A b N/A N/A N/A
13-Deoxytedanolide T 27 Methyl 3-oxopentanoate [220]
Diacarnoxide B N/A N/A N/A N/A
Diazonamide A T 20 7-benzyloxyindol [221]
Dictyoceratin C T 11 4-Hydroxy-3-methylbenzoic acid [222]
Dictyostatin-1 T 19 2-Vinyl-1,3-dioxolane [223]
Didemnin B T 9 Ethyl lactate [224]
Discodermolide T 36 trans-Pentadiene [225]
Dolastatin-10 T 11 (S)-Boc-proline [226]
Dolastatin-15 T 10 L-Hydroxyisovalelic acid [227]
Eleutherobin T 27 (R)-(´)-α-Phellandrene [228]
Ethylsmenoquinone N/A N/A N/A N/A




T/S a # of Steps Starting Material Reference
Fascaplysin T 2 Tryptamine [229]
Fijianolides A and B (Laulimalide) N/A N/A N/A N/A
Frondoside A N/A N/A N/A N/A
Furospinosulin-1 T 4 3-(3-furyl)propan-1-ol [230]
Furospongolide T 8 Geranyl acetate [231]
Geodiamolide A T 15 (´)-4-methylbutyrolactone [232]
Geodiamolide B T 13 D-tyrosine benzyl ester [233]
Geodiamolide H N/A N/A N/A N/A
Girodazole T 8 [234]
Halichondramide N/A N/A N/A N/A
Halichondrin B T 38 2-deoxy-L-arabinose diethyl thioacetal 4,5-acetonide [235]
Hemiasterlin A N/A N/A N/A N/A
Heteronemin N/A N/A N/A N/A
Hippuristanol S 15 Hydrocortisone [236]
14-Hydroxymethylxestoquinone N/A N/A N/A N/A
7-Hydroxyneolamellarin A N/A N/A N/A N/A
Z-4-Hydroxyphenylmethylene CA d N/A N/A N/A
Hyrtioreticulins A and B N/A N/A N/A N/A
Ianthelline T 5 3,5-dibromo-4-hydroxybenzaldehyde [237]
Iejimalides B and C T 15 Methyl (E)-3-bromo-2-methylacrylate [238]
Ilimaquinone T 17 Wieland-Miescher enone [239]
Irciniastatin A (psymberin) T 31 (´)-pantolactone [240]
Irciniasulfonic acid T 11 Hex-1-yne [241]
Isobatzellines A-D T 13 4-aminoveratrol [213]
Kahalalide F T 10 2-chlorotrityl chloride-resin [242]
Kendarimide A N/A N/A N/A N/A
Lamellarin D T 11 Vanillin and isovanillin [243]
Lasonolide A T 34 2,2,5-Trimethyl-1,3-dioxane-5-carbaldehyde [244]
Latrunculin A T 13 L-cysteine ethyl ester hydrochloride [245]
Laulimalide T 7 3,4-dihydro-2[2-methyl-4-pentyn-1-yl]-4-(phenylmethoxy) [246]
Leucettamol A N/A N/A N/A N/A
Luffariellolide T 8 Geranyl Bromide [247]
Makaluvamines A, C T 15 2-bromo-5-methoxy-benzenamine [248]
Manadosterols A and B N/A N/A N/A N/A
Manzamine A T 18 2-(bromomethyl)-2-ethenyl-1,3-dioxolane [249]
Meridianin E T 11 5-bromo-2-hydroxybenzaldehyde [250]
Microsclerodermin A N/A N/A S-citronellol [251] c
Mirabilin G N/A N/A N/A N/A
Monanchocidin A N/A N/A 3-azidopropanoic acid [252] c
Mycalamide A T 33 Diethyl-D-tartrate [253]




T/S a # of Steps Starting Material Reference
Mycothiazole T 16 4,4-dimethyl-5-(phenylmethoxy)-2-penten-1-ol [254]
Myriaporone 3 T 27 Methyl-(S)-(+)-3-hydroxy-2-methylpropionate [255]
Myriaporone 4 T 27 Methyl-(S)-(+)-3-hydroxy-2-methylpropionate [255]
Nakiterpiosin T 23 3-bromo-2-methylbenzenecarboxylic acid [256]
Neoamphimedine T 10 2,5-Dimethoxy-3-nitrobenzoate [257]
Neopetrosiamides A and B T 4 Resin-bound linear peptide [258]
Netamine M N/A N/A N/A N/A
Ningalin B T 8 6-Bromoveratraldehyde [259]
Onnamide A T 5 5-iodopentadienoic acid [260]
Pachastrissamine (jaspine B) T 8 6-heptenal [261]
Palau’amine T 28 3-cyclohexene-1-carboxylic acid [262]
Pateamine A T 29 Dimethyl L-malate and S-methyl 3-hydroxy-2-methylpropionate [263]
Peloruside A T 22 3-Methyl-1-butyne [264]
Petrosaspongiolide M N/A N/A N/A N/A
Philinopside A and E N/A N/A N/A N/A
PM050489 T 35 1,3-Propanediol [265]
PM060184 T 33 1,3-Propanediol [265]
Psammaplin A T 5 3-bromo-4-hydroxybenzaldahyde [266]
Psammaplysene A T 5 4-Iodophenol [267]
Renieramycin M T 21 N-Trityl-L-serine methyl ester [268]
Ritterazine B N/A N/A N/A N/A
Salicylihalamide A T 16 ethylene glycol [269]
Sarcodictyin A T 25 (+)-Carvone [270]
Sceptrin T 25 L-Glutamic acid [271]
Secobatzellines A and B T 12 2,4,5-trimethoxy-benzaldehyde [272]
Simplextone C N/A N/A N/A N/A
Sipholenol A N/A N/A N/A N/A
Sodwanone V N/A N/A N/A N/A
Spisulosine (ES-285) T 9 (S)-Garner’s aldehyde. [273]
Spongiacidin C N/A N/A N/A N/A
Spongistatin 1 (Altohyrtin A) T 27 (S)-glycidol [274]
Stelletin A N/A N/A N/A N/A
Strongylophorine 8 and 26 N/A N/A N/A N/A
Subereamolline A T 10 2-Hydroxy-4-methoxybenzaldehyde [275]
Thorectidaeolide A N/A N/A N/A N/A
Trabectedin T 28 1,3-propanodiol [276]
Variolin B T 8 4-chloro-2-methylthiopyrimidine [277]
Vitilevuamide N/A N/A N/A N/A
Waixenicin A N/A N/A N/A N/A
Zampanolide T 20 D-(´)-Aspartic acid [278]
a: T = total synthesis, S = hemisynthesis; b: N/A = synthesis not available; c: only partial synthesis reported; d: commercially available.
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We also hope that the table will be useful to synthetic chemists looking for a challenge presented
by natural products with significant anticancer potential but poorly (long synthetic sequence) or
currently inaccessible (N/A) through synthesis. From this perspective, we want to specifically draw
attention to marine invertebrate metabolites with, in our opinion, most promising anticancer activities
and currently poorly accessible as discussed in the following paragraphs.
Structurally unique, the pederin-type metabolite mycalamide A (58, Figure 12) initially isolated
from an unspecified marine sponge Mycale sp. [279], received great attention since its discovery
due to its in vitro cytotoxicity against several human cancer cell lines with nanomolar potency [280].
Mechanistic studies revealed that mycalamide A anticancer effect derives, at least partially, from its
binding to the 80S ribosome and inhibition of protein synthesis [281]. Furthermore, the spongean
metabolite was also reported to lead to the inhibition of oncogenic nuclear factors, which may indicate
a potential cancer-preventive effect [280].Mar. Drugs 2016, 14, 98  22 of 38 
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Figure 12. Structures of mycalamide A (58), spongistatin 1 (59), stelletin A (60), monanchocidin A (61),
phenylmethylene hydantoin (62), and frondoside A (63).
Mycalamide A has been reported from several sponge species, however being found in minute
and inconsistent amounts ranging from 0.00025%–0.0011% of the sponge wet weight [279,282,283].
Despite this unattractive scenario, Page et al. [109] verified that through the in-sea aquaculture of the
sponge Mycale hentscheli, mycalamide A could eventually be obtained in relatively higher amounts.
Curiously, this metabolite was also obtained from the ascidian Polysincraton sp., but analogously to the
previous reports, only 5.2 mg ere obtained from 1000 g of the animal wet weight [284]. An alternative
approach for the sustainable supply of mycalamide A through heterologous expression can also be
hypothesized due to the structural similarity with pederin, for which the putative trans-AT-PKS cluster
has been already identified [160].
This metabolite has been shown to be accessible through total synthesis and a number of such
completed endeavors has been reported, of which the synthesis by Rawal and coworkers appears to be
the shortest one, involving 33 steps [253]. It is thus unlikely that significant quantities of material can
be prepared with the currently available synthetic sequences for its further preclinical evaluation. The
presence of 10 stereocenters in the structure should be quite attractive to synthetic chemists seeking
applications of their stereoselective synthetic methodologies. Given the promise of mycalamide A as
an anticancer agent, the development of shorter syntheses is warranted.
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Almost simultaneously reported by Pettit and Kobayashi groups, from the sponges Spongia sp. [285]
and Hyrtios altum [286] respectively, spongistatin 1 (59, Figure 12) displayed an extremely potent and
selective in vivo cytotoxic activity at picomolar concentrations in the NCI 60 panel of human cancer
cell lines [287], including chemoresistant cancer cell lines [285,286]. Spongistatin 1 was found to retain
its remarkable anticancer effect also in vivo, displaying a potent effect against several tumor xenografts
without significant associated toxicity [288]. While spongistatin 1 anticancer mechanism has not
yet been completely elucidated, its promising anticancer properties include an inhibitory action on
tubulin polymerization [287], an anti-metastatic effect [288] and caspase-independent pro-apoptotic
activity [289]. The spongean metabolite was isolated from five distinct sponges but in extremely low
yields (0.003–0.17 mg/kg wet weight) [98], and the lack of further reports on its large-scale supply
through aquaculture, indicates that such an approach may be unfeasible. Currently, the shortest
synthesis of this metabolite was reported by the Smith’s group [274], which involves 27 steps. This
synthesis is currently being optimized by this group [274] for a scalable gram-quantity production.
The analysis of spongistatin’s 1 structure (59, Figure 12) reveals that such a goal presents a daunting
challenge, but should be highly rewarding from both fundamental and applied science perspectives.
The spongean cytotoxic agents stelletin A (60, Figure 12) and monanchocidin A (61, Figure 12)
hold great promise as potential candidates for further development as anticancer agents [290,291].
Both metabolites were found to induce autophagy in human cancer cell lines [292,293], in addition
to a significant in vitro antiproliferative effect against leukemia cell lines [291,292,294]. Furthermore,
monanchocidin A cytotoxic effect against genitourinary cancer cell lines was remarkably selective,
compared to non-malignant genitourinary cells [293].
Although identified in several sponge species, stelletin A’s low concentration in these natural
matrixes (<0.012% of sponge wet weight) clearly limits an eventual large-scale supply directly from the
natural sources [290,295,296]. The isolation yield of monanchocidin’s A from Monachora pulchra
constitutes only 1.54 mg of the compound from nearly 50 g of sponge dry weight [291,297].
No completed total syntheses for either metabolite have been reported, although structurally (60 and 61
in Figure 12) they appear to represent ample opportunities for synthetic chemists to test new
methodologies and ultimately develop scalable syntheses of these natural products.
Isolated from the marine sponge Hemimycale arabica, phenylmethylene hydantoin (62, Figure 12)
and several derivatives exhibited a significant in vitro cytotoxic effect against human cancer cells as
well as in vivo activity in PC-3M and MDA-MB-231 xenografts [298–300]. Remarkably, the spongean
metabolite and some of its synthetic derivatives were also found to display anti-invasive and
anti-metastatic properties, both in vitro and in vivo [299,300]. This compound has a very simple
structure and is commercially available or easily accessible via one-step synthesis from commercially
available inexpensive starting materials. This easy access to large quantities of phenylmethylene
hydantoin and promising anticancer potential should encourage its further preclinical studies.
Targeting several signaling pathways, the triterpenoid glycoside frondoside A (63, Figure 12)
has been reported as a promising anticancer agent leading to an in vitro and in vivo growth inhibitory
effect in several human cancer cell lines [301,302]. Furthermore, frondoside A anticancer effect
was also associated to its anti-invasive, anti-migratory and anti-metastatic properties, reported in
breast [303,304] and lung cancer cells [305]. Frondoside A was initially reported more than 20 years
ago as a metabolic product of the sea cucumber Cucumaria frondosa [306] and was later discovered in
Cucumaria okhotensis in extremely low concentrations (4.4 mg from 1.4 kg of dried animal residue) [307].
So far no synthetic studies have been reported for this triterpene glycoside, although it appears
that its terpenoid and glycosidic portions of the molecule should present an interesting challenge
to the synthetic community to apply the ample current know-how for the construction of these
structural frameworks.
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2.8. Hybrid Strategies
In addition to the mainstream and widely used classical semisynthetic strategy, further elegant
technologies combining microbial genetics, fermentation, and chemical synthesis can provide key
intermediates or even the desired metabolite produced in minute quantities by a marine invertebrate.
The identification of gene clusters involved in the production of secondary metabolites allows the
generation of new intermediates through combinatorial biosynthesis, exploiting the ability of biological
systems to generate complex chemistry, for example, via the manipulation of components from a
metabolic pathway such as PKS and NRPS genes, or through the combination of genes from distinct
organisms [308–311]. Additional approaches are mutasynthesis and chembiosynthesis, which have
been successfully applied in the commercial synthesis of several drugs [310].
Another technology involves the combination of molecular engineering, microbial fermentation,
and chemical synthesis, which has been achieved for the production of the tubulin-interactive agent
discodermolide (21, Figure 4). The generation of key intermediates by genetically modified Streptomyces
strains, carrying a mutated PKS gene and fed with specific unnatural precursors, facilitated the
post-fermentation production of discodermolide by chemical synthesis [312]. Posteriorly to the
remarkable achievement on the heterologous expression of patellamides, a novel cyclic peptide
eptidemnamide was generated by modification of the patellamide genes [69]. The potential of these
combined approaches relies not only in the possibility of generating intermediates of natural products
obtained in insufficient quantities from their natural source, but also in the construction of libraries of
analogues, structurally related to a lead compound, that may have improved pharmacological activity.
3. Future Prospects
The last two decades have witnessed intensive efforts to utilize marine invertebrates for the
provision of molecules with anticancer activities. The importance of marine compounds in drug
research is demonstrated by the fact that around 50% of the FDA-approved drugs during the period
1981–2014 are either marine metabolites or their synthetic analogues [313–315]. The US NCI estimates
that more than 1% of marine natural products show antitumor properties as compared to the 0.01% of
their terrestrial counterparts [316]. Gerwick and Moore [313] reported in 2012 that the success rate of
discovery from the marine world for any type of clinical indication (seven drugs from 22,000 discovered
molecular entities, i.e., one drug per 3140 natural products described) is 1.7 to 3.3–fold higher than the
industry average (one drug from 5000–10,000 tested compounds). However, the lack of a sustainable
large-scale supply of marine-sourced drugs or drug candidates has been and continues to be one of the
main challenges in pharmacology.
Wild harvest of marine invertebrates can in many cases provide sufficient amount of material for
preclinical studies. However, clinical development and commercial production of successful agents
necessitates large collections of marine organisms, which is environmentally unsustainable due to
the poor abundance of their natural populations and low isolation yields of the bioactive metabolites.
While the scale-up of marine invertebrate-derived metabolites for clinical development through
aquaculture may play its part, this strategy can be only considered in a very limited number of cases.
Even with the optimization of growth parameters this approach is usually economically daunting
as described by the development of trabectedin. Despite the progress in culturing of invertebrate
cells, this technique is far from being able to offer a sustainable supply of metabolites in the near
future. In contrast, the recognition that a significant number of anticancer agents originally reported as
invertebrate-derived may possibly have a bacterial origin, brings much hope to not only to solving
the supply problem but also to the creation of new drug leads. Recombinant technologies such as
the heterologous expression of biosynthetic pathways have been a major focus in recent years, and
despite the above-mentioned limitations, the successful production of patellamides paves the way and
demonstrates that this approach may be viable in the upcoming years.
Chemical synthesis has been and in all likelihood will continue to be indispensable in obtaining
marine invertebrate-derived drugs and promising drug candidates in quantity. The fact that all four
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currently approved drugs are produced by synthesis is excellent testimony to the significance of this
resource. As can be seen in the Figures contained in the current review, marine natural products
stand out due to their complex structures incorporating multicyclic carbon skeletons and numerous
stereogenic centers. On one hand, this raises the bar for organic chemists to develop scalable pathways
to these formidable synthetic targets. On the other hand, this could be a blessing in disguise as these
structures attract numerous organic chemists looking for an academic total synthesis journey and
laying the paths to these complex molecules. These synthetic routes can often be later optimized for
gram or even kilogram scale production, as we have seen in the cases of trabectedin and Halaven®.
We hope that the synthetic chemistry described in this review as well as the discussion of the anticancer
activities associated with many marine invertebrate-derived molecules will stimulate further interest
in the synthetic community to help develop new life-saving medicines while advancing the science of
chemical synthesis from the fundamental perspective.
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